"We have a cautious outlook on both (Spikevax and mResvia)," Leerink Partners analyst Joseph Stringer said in a report. "We believe Covid vaccination rates will decline faster than expected and mResvia will face competitive pressure from approved RSV vaccines Arexvy and Abrysvo."